Tyrosine kinase signaling-independent MET-targeting with CAR-T cells

• Published in: Journal of translational medicine Vol. 21; no. 1; pp. 682 - 17
• Main Authors: Qin, Anna, Qin, Yuan, Lee, Joseph, Musket, Anna, Ying, Mingyao, Krenciute, Giedre, Marincola, Francesco M, Yao, Zhi Q, Musich, Phillip R, Xie, Qian
• Format: Journal Article
• Language: English
• Published: England BioMed Central 01-10-2023; BMC
• Subjects: Animals; Antibodies; Antigens; Apoptosis; c-Met protein; Cancer immunotherapy; Cancer therapies; Carcinoma, Hepatocellular - pathology; CD28 antigen; Cell death; Cell Line, Tumor; Cell therapy; Chimeric antigen receptor T cell therapy; Chimeric antigen receptors; Clinical trials; Cloning; Cytokines; Cytokines - metabolism; FDA approval; Flow cytometry; Hepatitis B; Hepatocellular carcinoma; Humans; Immunotherapy, Adoptive; Kinases; Liver cancer; Liver Neoplasms - pathology; Lymphocytes; Lymphocytes T; MET tyrosine kinase receptor; Mice; PD-1 protein; Programmed cell death protein 1 (PD-1); Protein-tyrosine kinase receptors; Protein-Tyrosine Kinases - metabolism; Proteins; Signal Transduction; Solid tumors; T cell receptors; T-Lymphocytes; Xenograft Model Antitumor Assays; Programmed cell death protein 1 (PD-1); Hepatocellular carcinoma; MET tyrosine kinase receptor; Cancer immunotherapy; Chimeric antigen receptor T cell therapy
• ISSN: 1479-5876; 1479-5876
• DOI: 10.1186/s12967-023-04521-9

Recent progress in cancer immunotherapy encourages the expansion of chimeric antigen receptor (CAR) T cell therapy in solid tumors including hepatocellular carcinoma (HCC). Overexpression of MET receptor tyrosine kinase is common in HCC; however, MET inhibitors are effective only when MET is in an active form, making patient stratification difficult. Specific MET-targeting CAR-T cells hold the promise of targeting HCC with MET overexpression regardless of signaling pathway activity.
MET-specific CARs with CD28ζ or 4-1BBζ as co-stimulation domains were constructed. MET-CAR-T cells derived from healthy subjects (HS) and HCC patients were evaluated for their killing activity and cytokine release against HCC cells with various MET activations in vitro, and for their tumor growth inhibition in orthotopic xenograft models in vivo.
MET-CAR.CD28ζ and MET-CAR.4-1BBζ T cells derived from both HS and HCC patients specifically killed MET-positive HCC cells. When stimulated with MET-positive HCC cells in vitro, MET-CAR.CD28ζ T cells demonstrated a higher level of cytokine release and expression of programmed cell death protein 1 (PD-1) than MET-CAR.4-1BBζ T cells. When analyzed in vivo, MET-CAR.CD28ζ T cells more effectively inhibited HCC orthotopic tumor growth in mice when compared to MET-CAR.4-1BBζ T cells.
We generated and characterized MET-specific CAR-T cells for targeting HCC with MET overexpression regardless of MET activation. Compared with MET-CAR.4-1BBζ, MET-CAR.CD28ζ T cells showed a higher anti-HCC potency but also a higher level of T cell exhaustion. While MET-CAR.CD28ζ is preferred for further development, overcoming the exhaustion of MET-CAR-T cells is necessary to improve their therapeutic efficacy in vivo.